Vistagen, a late-stage biopharmaceutical company, announced that its clinical development program for fasedienol nasal spray has achieved minimum safety exposure requirements under ICH E1, the international regulatory standard governing safety databases for long-term drug development. As of May 31, the company estimates over 1,500 subjects have received at least a single exposure to fasedienol, over 300 subjects have been exposed for at least 6 months, and over 100 subjects for at least 12 months. These numbers represent completed visits in the fasedienol open-label safety studies and include ongoing participation in extension studies. The company emphasized that achieving these exposure recommendations marks significant progress, though final FDA alignment on exposure requirements for a potential New Drug Application (NDA) submission remains pending.
Fasedienol is in Phase 3 development for acute treatment of social anxiety disorder, a psychiatric condition affecting over 30 million adults in the U.S. The disorder can manifest acutely in anxiety-provoking social situations and is associated with depression, substance use disorders, and suicidal ideation. Fasedienol operates via a proposed mechanism distinct from all FDA-approved anti-anxiety medications: when administered intranasally in microgram-level doses, it modulates nasal-limbic amygdala fear and anxiety circuits. Unlike benzodiazepines, fasedienol shows no observed potentiation of GABA-A receptors and no observed binding to dopamine or opiate receptors—factors associated with abuse liability in other psychiatric medications.
Clinical development timeline
Topline results from PALISADE-4, the randomized placebo-controlled Phase 3 trial, are expected in the second quarter of this year. Results from the Phase 2 Repeat Dose study are anticipated in the third quarter. The company indicated that successful PALISADE-4 results, combined with positive findings from the earlier PALISADE-2 Phase 3 trial and evidence of clinical meaningfulness regarding duration and magnitude of effect, could support an NDA submission. Fasedienol has received FDA Fast Track designation for development in acute social anxiety disorder and has been well-tolerated across completed trials to date.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.timesargus.com/news/business/vistagen-achieves-minimum-ich-safety-exposure-recommendations-across-clinical-program-for-fasedienol-for-the-acute/article_492eed20-2647-5156-ac55-c7587c089722.html